TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| MDI completes reverse stock split MDI Inc. has completed a 1-for-10 reverse stock split that had been previously announced. The company’s common shares are now trading on a split-adjusted basis under the trading symbol MDIZ.PK. feeds.bizjournals.com |
Rodman Conference Recaps: EXACT Sciences, Delcath, Unilife Mike Havrilla submits:On 8/31/09, Delcath Systems (NASDAQ:DCTH) announced the FDA granted orphan drug status to doxorubicin, an approved chemotherapy agent, for the treatment of primary liver cancer. The company said it tested doxorubicin with its unique drug delivery technology, Percutaneous Hepatic Perfusion (PHP), which results in significantly higher doses (e.g. 10X the FDA approved standard dosing with 100X exposure of drug to the tumor site) of anti-cancer drugs such as doxorubicin to the liver without exposing the patient's entire body. Delcath plans to carry out the necessary clinical work for a regulatory submission of PHP with doxorubicin. Click here for a YouTube ABC News video on my personal blog site which describes the PHP System and provides a case study of a patient with liver cancer. Complete Story » seekingalpha.com |
Public Faces Long Wait for Flu Vaccine State and local budget cuts coupled with limits on who can administer the new swine-flu vaccine could hamstring efforts to delivery doses to anyone who wants it. online.barrons.com |
XOMA Ltd. Q3 2009 Earnings Call Transcript XOMA Ltd. (XOMA)Q3 2009 Earnings CallNovember 9, 2009 9:00 am ETComplete Story » seekingalpha.com |
Pfizer Forms Cancer Collaboration with Crown Bioscience ChinaBio Today submits: Crown Bioscience, a pre-clinical CRO providing biology services for oncology indications, will collaborate with Pfizer (NYSE: PFE) to research and develop novel drugs for cancers that are prevalent in Asia and remain unaddressed medical needs. Crown will receive an upfront payment and research funding, as well as milestone payments upon achieving preclinical and clinical goals. The companies did not disclose specific financial details of their arrangement.Crown, which is headquartered in Santa Clara, CA, has labs in Carmel, IN, Beijing and Taicang (near Shanghai), the company’s newest facility. The Taicang lab will carry out the work for Pfizer, which will be to discover and advance multiple candidates for clinical development. Crown held a Grand Opening for the new lab this past Sunday. It was attended by 100-200 guests, including many of Pfizer's senior executives. Steve Yang, PhD, Vice-President of Pfizer and Head of R&D-Asia was one of the attendees. Complete Story » seekingalpha.com |